Replies to post #11232 on RespireRx Pharmaceuticals Inc (RSPI)

[food4thought]

Aiming,
I guess I was looking for some insightful answers to justify my currently overweighted position in COR. I am looking for worst and best case scenarios to evaluate forward risk. Speculation is just that. I was hoping maybe an e-mail or other first hand contact with COR might have brought some verification to COR's future. I certainly do not want to sell here and it is just as hard to add to my position without knowing our plans going forward. I do believe everyone here understands the exponetial possiblities if COR can ever manage to advance one or several of their compounds but certainly time is of the essence and I am not sure current managemnet is going to be able to sufficiently manage our current cash situation.
I believe I read on this board that Stoll is over 60 years of age. Does that not raise some questions? He is paid handsomely and is probably near retirement which raises questions regarding his level of aggressiveness.
All of the suggestions of buyout, merger, BP intervention etc. sound great but what is the reality? I appreciate your thoughts and will weigh them with others. I certainly am holding until the conference call and will weigh my position at that time. Good luck and thanks for this board, although right now I fear it may have contributed to my somewhat undesirable situation.

[jerrydylan]

I keep going back to the conversation I had with Roger on wednesday, I sensed disappointment but not desperation and I think with the money sloshing around BP looking for hope out there , our future lies in a larger Global partnership. Cortex would be working "for" someone again- but it would insure that those massive options retain value. Aiming's points are what I think needs to be viewed with some favorability and likeliness. I note Ron Garren sold....( he never traded it well anyway) and joined Piros in recommending the selling of the company. He also said the target remains an exciting one and that Cortex does not have the 'horsepower' ( his word) to develop it. I think he is right sans bigger deal with a Schering Plough, Pfizer ect....- Say Stoll has one in his back pocket....they all wanted CX-717 alongside the high impact deal he walked away from- and assume they wanted CX-717 for ADHD only. He told me straight up CX-701 was not dead for ADHD,I asked is CX-701 dead for ADHD? his words..." Oh no, it would probably go gangbusters in that"......So, what can you read from that? I think the tox issue with CX-717 and it's initial occurence was it's own lead ballon. It had too high a MG count/ small a half-life to work at low doses, plus....think Vioxx, it had tox issues that were glossed over in an earlier period, pre-clinical. That is now and forever the rule of thumb.